Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Cells and Metastasis, Cancer Genomics and Diagnostics, Immunotherapy and Immune Responses, and Cancer Research and Treatments.
Ex vivo drug testing in metastatic biopsies reveals patient-specific vulnerabilities to cancer targeting and immune activating drugs
MCSP+ metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization
Cortical organoid-derived models of the melanoma brain metastatic niche enable prioritization of cancer-targeting drugs
Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients
Abstract 3788: EpCAM+ DCCs isolated from the bone marrow of breast cancer patients display high stemness and potency scores
Abstract 4124: Patient-derived ex vivo models to test drug responses of disseminated cancer cells in various metastatic niches
Abstract 5530: Metastasis founder cells activate immunsuppression early in human metastatic colonization
Metastasis founder cells activate immunosuppression early in human melanoma metastatic colonization
Ex vivo expansion of lung cancer‐derived disseminated cancer cells from lymph nodes identifies cells associated with metastatic progression
Abstract IA024: Cellular plasticity during metastatic colony formation in patients
Data from Combined Genome and Transcriptome Analysis of Single Disseminated Cancer Cells from Bone Marrow of Prostate Cancer Patients Reveals Unexpected Transcriptomes
Data from Combined Genome and Transcriptome Analysis of Single Disseminated Cancer Cells from Bone Marrow of Prostate Cancer Patients Reveals Unexpected Transcriptomes
Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation
Retrospective cell lineage reconstruction in humans by using short tandem repeats
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency
Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency
Therapy resistance beyond cellular dormancy
Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA
Abstract LB-312: Interleukin 6 transsignaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency
Abstract 431: Semi-automated detection, isolation and molecular analysis of single disseminated melanoma cells from lymph nodes
Abstract LB-312: Interleukin 6 transsignaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency
Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma
Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma
The sentinel lymph node spread determines quantitatively melanoma seeding to non-sentinel lymph nodes and survival
PO-440 Development and characterisation of pre-clinical in vitro/in vivo models from disseminated tumour cells of melanoma patients
Abstract LB-363: Characterization of in vitro and in vivo models generated from disseminated tumor cells of patients without manifest metastasis
Retrospective cell lineage reconstruction in Humans using short tandem repeats
Early dissemination seeds metastasis in breast cancer
Combined Genome and Transcriptome Analysis of Single Disseminated Cancer Cells from Bone Marrow of Prostate Cancer Patients Reveals Unexpected Transcriptomes
Immune Humanization of Immunodeficient Mice Using Diagnostic Bone Marrow Aspirates from Carcinoma Patients